What is an indication for milrinone?

• Simvastatin: Simvastatin is a statin medication used to lower LDL cholesterol and total cholesterol in clients with hypercholesterolemia. It works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver. Statins reduce the risk of atherosclerotic cardiovascular disease and are part of long-term management of elevated lipid levels.

• In the evening: Cholesterol synthesis in the liver is highest at night. Administering simvastatin in the evening optimizes its effectiveness in lowering LDL and total cholesterol levels. Educating clients about timing improves medication efficacy and supports adherence to therapy.

• Dark urine: Dark urine may indicate rhabdomyolysis, a rare but serious adverse effect of statins, caused by muscle breakdown. Clients should report this immediately, as it can lead to acute kidney injury. Prompt recognition and discontinuation of the medication are essential to prevent severe complications.

A. A client needing stroke prevention: Antiplatelet therapy is indicated for clients at risk of ischemic stroke or recurrent stroke because it helps prevent platelet aggregation, reducing the likelihood of clot formation in the arteries. This intervention is especially beneficial in clients with a history of transient ischemic attacks or atherosclerotic cardiovascular disease.

B. A client with a vitamin K deficiency: Vitamin K deficiency primarily affects clotting factor synthesis, leading to a bleeding tendency. Antiplatelet therapy would increase the risk of bleeding in these clients, making it contraindicated rather than indicated.

C. A client with a low platelet count: Clients with thrombocytopenia are already at risk for bleeding, and antiplatelet therapy would further impair clot formation, increasing the potential for hemorrhage. It is therefore avoided in these situations.

D. A client diagnosed with leukemia: Leukemia can be associated with low platelet counts or abnormal platelet function, placing the client at risk for bleeding. Administering antiplatelet therapy could exacerbate hemorrhagic complications rather than provide benefit.